Lost in all the excitement yesterday was the lack on mention of the alkaline phosphatase story and the upcoming ASN Kidney Week presentations. ASN meeting is Nov 5-10 next week and Resverlogix has 3 abstracts.

November 8th: 1048: Apabetalone Lowers Serum Alkaline Phosphatase in CVD Patients with and Without CKD and Improves Cardiovascular Risk

November 8th: 317: Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome

November 9th: 782: Apabetalone Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk

The above abstracts to be presented at ASN are likely just based on previous Phase 2 data, previously published data, and BETonMACE baseline data. This will be a great set up to get the bases loaded for the grand slam at AHA. We've got a couple of batters ready to hit that home run sometime between Nov 16-18. If Dr. Kausik Ray doesn't swing for the fences in his Nov 16th AHA late breaker, then Don McCaffrey will surely step up to the plate on the pre-market webcast on Nov 18th to swing away.

By the time the Nov 18th AHA poster below is presented, the kimono will have been lifted and they will have free rein to talk about any and all alkaline phosphatase (ALP) assocations in BETonMACE....not just baseline data. Sounds like Mr. McCaffrey wants to reveal everything minus the cognition data by Nov 18th. Ay carumba gran oso es muy excitado!

November 18th: ALP Levels Predict Adverse Cardiovascular Outcomes and Cognitive Impairment in High Risk Patients